Teva
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Israel · 10K+ Employees
View Company Info for Free
Overview
Headquarters
124 Dvora Hanevi'a St, Tel Aviv, Tel Avi...Phone Number
+972 39148213Website
www.tevapharm.comRevenue
$17.3 BillionStock Symbol
TEVAIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
15
1
2
2
2
2
About Teva
Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader focused on improving health outcomes for patients worldwide. Enabled by a world-class generics business, Teva develops, manufactures, and delivers a broad portfolio of medicines, including complex generics, biosimilars, innovative therapies, and pharmacy brands. The company is dedicated to addressing unmet patient needs by advancing scientific research, expanding access to quality medicines, and streamlining the delivery of treatments -from established generics to cutting-edge therapeutic solutions.Explore more
Teva Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Teva your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Teva
Product Launch: Get notified when Teva launches new products
Teva, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Teva has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Teva recently announced quarterly report
Funding: Get notified immidiatlly once Teva has new funding data
Click to see if Teva had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Teva is spiking on competitors!
Recommended Actions
Find VP level buyers at Teva
Find 3 more new buyers
Compare Similar Companies to Teva
Compare insights from companies similar to Teva, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Teva
$17.3B
10K+
Public
$99.3B
1901
BS
Brian SavageExecutive Vice President & Interim Chief Legal Officer
$72.2B
10K+
Public
-
1876
Hideyuki TozakiDirector, Research & Development & Chief Operating Officer, Oncology
$56.7B
10K+
Public
-
1996
DC
Daniela CastanedaImmunology Director, Commercial Operations & Chief of Staff
Company Profile Activity
Activity Insights
Teva is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Teva is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Teva.
Teva financials insights
Gather financial insights about Teva, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Multiple Rounds
$11.3B
2012
Multiple Rounds
$7.6B
2015
Debt
$2.4B
Debt
$33.8B
2016
Multiple Rounds
$28.1B
2018
Corporate Investment
$358M
Debt
$4.5B
2019
Debt
$2.3B
2026
Private Equity
$400M
Teva Tech Stack
A closer look at the technologies used by Teva
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Teva has announced that its long-acting olanzapine product is expected to generate meaningful revenue beginning in H2 2027, with a target of creating a $1.5 to $2 billion psychiatric franchise.
Earnings, Pharmaceuticals, Finance
Product Launch
Teva has announced plans to launch ecopipam, a treatment for Tourette syndrome acquired through the Emalex Biosciences deal, with a base case launch timeline of mid to late 2027, supported by synergies with the existing neurology franchise and the addition of a dedicated pediatric sales force.
Product Launch, Sales
Product Launch
Product Launch, Pharmaceuticals
Teva News & Media
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but at what cost to stability?Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
TEL AVIV, Israel and ZUG, Switzerland, July 09, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma BiolTeva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
Teva will hold an investor call and live webcast today, Tuesday, July 7, 2026, at 8:00 a.m. ET to discuss these data.Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Teva
Sign Up For FreeTo access detailed company insights
Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader focused on improving health outcomes for patients worldwide. Enabled by a world-class generics business, Teva develops, manufactures, and delivers a broad portfolio of medicines, including complex generics, biosimilars, innovative therapies, and pharmacy brands. The company is... Read More
